Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | ESR1 | P03372 | 13/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 13/20 | 0.39 |
| ▸ | ESRRB | O95718 | 1/20 | 0.38 |
| ▸ | ESRRA | P11474 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 2/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2566786 | 0.82 | ESRRB (0.53) | PTGS2ESR1ESR2ESRRBESRRA | |
| SCHEMBL2180565 | 0.77 | ESR2 (0.47) | PTGS2ESR1ESR2MIFPTGS1 | |
| SCHEMBL2564011 | 0.77 | ESR1 (0.58) | PTGS2ESR1ESR2MIFPTGS1 | |
| SCHEMBL8934596 | 0.77 | ESR1 (0.58) | PTGS2ESR1ESR2MIFPTGS1 | |
| SCHEMBL5854907 | 0.77 | ESR2 (0.41) | PTGS2ESR1ESR2ESRRBESRRA | |
| SCHEMBL2566862 | 0.76 | ESR2 (0.45) | PTGS2ESR1ESR2MIFPTGS1 | |
| SCHEMBL5854900 | 0.76 | ESR1 (0.55) | ESR1ESR2MIF | |
| SCHEMBL2571864 | 0.75 | ESR1 (0.48) | ESR1ESR2ESRRBESRRAMIF | |
| SCHEMBL243923 | 0.73 | ESR1 (0.54) | ESR1ESR2ESRRBESRRAPTGS1 | |
| SCHEMBL2567309 | 0.71 | ESR1 (0.59) | PTGS2ESR1ESR2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040102479-A1 | Novel benzopyran or thiobenzopyran derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2004-05-27 | — | — | US | disclosed |
| US-6645951-B1 | Antiestrogens for treating breast cancer | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-11-11 | — | — | US | disclosed |
| EP-1087959-A1 | NOVEL BENZOPYRAN OR THIOBENZOPYRAN DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065893-A1 | NOVEL BENZOPYRAN OR THIOBENZOPYRAN DERIVATIVES | C & C RESEARCH LABORATORIES (KR) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102479-A1 | Novel benzopyran or thiobenzopyran derivatives | NR5A1, SHBG, ESR2 | PTGS2 1019/4885ESR1 12/4885ESR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.